Ulcerative Colitis
Pipeline by Development Stage
Drug Modality Breakdown
Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.
Key Trends
- JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
- Multiple patent cliffs emerging 2026-2028, creating generic competition risk
- Robust pipeline with 4,996 trials signals continued innovation and market expansion
Career Verdict
Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MOUNJARO (TIRZEPATIDE) | Eli Lilly and Company | $2.4B | 16% | PEAK | Growing | 15.5yr |
| 2 | SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE) | AstraZeneca | $2.0B | 13% | LOE_APPROACHING | Stable | |
| 3 | JAKAFI (RUXOLITINIB) | Incyte | $1.9B | 13% | LOE_APPROACHING | Declining | 2.5yr |
| 4 | RESTASIS (CYCLOSPORINE) | AbbVie | $1.5B | 10% | PEAK | Stable | 7.9yr |
| 5 | RINVOQ (UPADACITINIB) | AbbVie | $976M | 7% | PEAK | Growing | 11.7yr |
Drug Class Breakdown
dominant class with patent cliff risk
established, mature market segment
driven by single blockbuster
established immunosuppression class
legacy biologic class with competition
Career Outlook
GrowingImmunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.
Breaking In
Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.
For Experienced Professionals
Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.
In-Demand Skills
Best For
Hiring Landscape
Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.
Top Hiring Companies
By Department
Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.
On Market (7)
Approved therapies currently available
Competitive Landscape
92 companies ranked by most advanced pipeline stage
+62 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 18,930 patients across 50 trials
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis
Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis
Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205)
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
Related Jobs in Immunology
Clinical Scientist - Immunology (Expertise in Ulcerative Colitis, Crohn’s disease and Rheumatology + Excel) - Clinical Drug Trial Exp - Must Have
Sr. Manager/ Associate Director, Statistical Programming
Sr. Manager/ Associate Director, Data Management
VP, Finance
Clinical Sales Specialist (ImmunoDiagnostics) - Philadelphia, PA
Executive Medical Director, Early Dev - Inflammation
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.